Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TRANSITION THERAPEUTICS INC. T.TTH

"Transition Therapeutics Inc is a product-focused biopharmaceutical company. The Company is engaged in developing therapeutics for disease indications with markets. Its technologies are focused on the treatment of Alzheimer's disease and diabetes."


TSX:TTH - Post by User

Comment by deninsaskon Mar 26, 2007 7:25pm
290 Views
Post# 12492964

RE: Conju results....Opinions from.... ..whocares

RE: Conju results....Opinions from.... ..whocares Hey Whocares......thats a tough one being that I don't follow Conju anymore and don't even know if it is still DAC driven technology or not. But the first thing that strikes me off the top of my head is that our Placebo Group did not show such big decreases in HbA1c levels and actually had increases further down the road therefore providing a better control group and showing a possibly better disciplined group of patients and shows to be statistically significantly better. Subtract placebo group from treatment group and what do you get??Blows conju out of the water. Oh here I found this quick on Transitions website. Note the placebo groups response compared to conju placebo group. HbA1c levels decreased from baseline by an average of 0.97% (p=0.0273) and 1.12% (p=0.0273) in months 2 and 3 post-treatment, respectively, while HbA1c levels in placebo patients decreased by an average of 0.08% in month 2 post-treatment and increased by 0.4% in month 3 post-treatment. Fasting blood glucose levels were reduced with an average decrease of 45 mg/dL (p=0.0234) at 3 months post-treatment compared to an increase of 16 mg/dL in the placebo patients. I would suggest you listen to the conference call for E1-INT again as many questions were answered that do not appear in the news releases. Some of which may help you with your comparisons. Good Luck all. Booooooyaaaaaaaaahh!!! Had to let that one OUT!!..............LOL
Bullboard Posts